Related news:
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone - Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales - Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio - Novartis not joining the 'frenzy' of weight loss drugs, CEO says - Siemens Healthineers boosts cancer imaging with EUR200mn Novartis deal - Novartis warns prostate cancer drug price will remain high - Novartis Raises Guidance as Key Drugs Boost Sales - Stocks making the biggest premarket moves: General Motors, GE Aerospace, Novartis, JetBlue and more - Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs
Novartis
Bookmark
ShareNovartis is a company. It is located in Basel, Switzerland and was founded in 1996. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry. Based on various external sources, the CEO's approval rating is 63 %.
Key facts
- city: Basel
- country: Switzerland
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1996
- CEO: Dr. Vasant Narasimhan
- CEO approval: 63 %
Classified as: organization
Business
Novartis is one of the companies in Switzerland, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Assets: 131.8B $
- Debt: 31.1B $
- Employees: 108,000 people
- Free cash flow: 11.7B $
- Market cap: 183.7B $
- Profits: 24B $
- Revenues: 52.8B $
Stocks from Novartis:
Talking Points:
- Novartis
- Working together, we can reimagine medicine to improve and extend people’s lives.
- Our purpose is to reimagine medicine to improve and extend people’s lives. See our community guidelines: https:
- t.co
- 8fvS5jsThu
- Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and ...
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Learn more about talking points
